Dive into some
exciting news

SeaStar Medical recognizes that key inflammatory messengers can be transformed. See how we're transforming medicine.

Disruptive thinking from a solutions-oriented organization

SeaStar Medical is a privately held, clinical-stage medical therapeutics company headquartered in Denver, Colorado. Our revolutionary Selective Cytopheretic Device (SCD) is in the final stages of clinical testing with an anticipated launch date in the second half of 2021.

For any media inquiries, please contact psconsulting@seastarmed.com.

Latest News

SeaStar Medical Presents Data from SCD 005 Clinical Study at the American Society of Nephrology (ASN) Kidney Week 2021 Annual Meeting

Results show promise for returning a dysregulated immune system to homeostasis in critically ill patients DENVER, CO, November 5, 2021— SeaStar Medical, a medical device company that has redefined how extracorporeal therapies may reduce excessive inflammation on vital organs, announced new data from its SCD 005 clinical study to evaluate the safety and feasibility of the Selective Cytopheretic Device (SCD) in COVID-19 patients with acute kidney injury (AKI) and/or acute respiratory distress syndrome (ARDS). The data were presented at the American Society of Nephrology (ASN) Kidney Week 2021 Annual Meeting. In the poster presentation, “SCD treatment in COVID-19 ICU Patients

Read more >

SeaStar Medical Completes Enrollment of SCD 005 Trial to Evaluate Safety of Selective Cytopheretic Device (SCD) in AKI as well as ARDS Patients with COVID-19

Findings from the study in patients with AKI and/or ARDS with COVID-19 infection are expected later this year DENVER, JUNE 17, 2021 — SeaStar Medical, a medical technology company delivering novel therapeutic solutions to improve organ function, announced today that the company has completed enrollment of the SCD 005 study to evaluate the safety of the Selective Cytopheretic Device (SCD) in patients with acute kidney injury (AKI) and/or acute respiratory distress syndrome (ARDS) with COVID-19 infection. This study builds on previous studies and continues to validate the SCD’s therapeutic approach. Findings are expected later this year. “Completing enrollment of the

Read more >

SeaStar Medical Announces Additions to Board of Directors

— Board members are industry leaders who will actively support company growth strategies — DENVER, Jan. 11, 2021 /PRNewswire/ — SeaStar Medical, a medical technology company delivering novel therapeutic immunomodulating solutions to improve organ function, announced today it has appointed Rick Barnett and Dr. Allan J. Collins to its board of directors, effective January 8, 2021.  “We are excited and honored to welcome Rick and Allan as new independent directors to the SeaStar Medical board, ” said Ray Chow, Chair of the Board of Directors of SeaStar Medical. “They join SeaStar Medical at an important time as we transition to commercializing our Selective Cytopheretic (SCD) therapeutic device. Rick

Read more >

SeaStar Medical Announces Positive Results from Pilot Clinical Study of the Selective Cytopheretic Device (SCD) in Pediatric Patients with Acute Kidney Injury

Study met primary and secondary endpoints related to survival and renal recovery at day 60. DENVER, Oct. 26, 2020 /PRNewswire/ — SeaStar Medical, a medical technology company delivering novel therapeutic immunomodulating solutions to improve organ function, today announced the results from the first every application of the Selective Cytopheretic Device (SCD) in pediatric patients with acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT). The study’s primary objective was to assess the safety of the SCD in children. Safety was determined by adverse events related to treatment up to 60 days following treatment initiation. Secondary outcome measures were mortality and renal replacement

Read more >

SeaStar Medical to present Data on Selective Cytopheretic Device (SCD) in Pediatric Patients with Acute Kidney Injury at American Society of Nephrology Kidney Week 2020

DENVER (PRWEB) OCTOBER 13, 2020 SeaStar Medical, a medical technology company delivering novel therapeutic immunomodulating solutions to improve organ function, today announced it will present Phase II clinical trial outcomes of its Selective Cytopheretic Device (SCD) at the virtual American Society of Nephrology (ASN) Kidney Week 2020 meeting which will take place October 22-25, 2020. The presentation will report on the feasibility and safety of the first-ever application of the SCD technology in critically ill children with acute kidney injury (AKI). The SCD has been tested in adults where it was associated with improved survival and reduced dialysis dependency at 60

Read more >

SeaStar Medical Appoints New Board Chairman To Deliver Growth

DENVER, May 21, 2020 /PRNewswire/ — SeaStar Medical, a medical device company focused on delivering novel immunomodulating medical device solutions to improve organ function, today announced the appointment of Ray Chow as chairman of its Board of Directors. Ray will lead the Board, working with the existing investors and any future investment groups. In addition, Ray will oversee Business Development and Global Partnership activities for SeaStar Medical. Ray has served as a member of the Board since 2019. He is the principal of Bio-Mondo Consulting, a management consultancy to the biopharmaceutical industry and has deep experience in global product launches, sales expansion and strategic

Read more >

The SCD is an investigational device and is not currently available for sale. Please check back for further updates on device availability in your region.